A Gene Transfer Therapy Study to Evaluate the Safety and Efficacy of Delandistrogene Moxeparvovec (SRP-9001) Following Imlifidase Infusion in Participants With Duchenne Muscular Dystrophy (DMD) Determined to Have Pre-existing Antibodies to Recombinant Adeno-Associated Virus Serotype (rAAVrh74)

Conditions: Duchenne Muscular Dystrophy Interventions: Genetic: delandistrogene moxeparvovec; Biological: imlifidase Sponsors: Sarepta Therapeutics, Inc.; Hansa Biopharma AB Enrolling by invitation
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials